title: [Therapeutic effects of umbilical cord mesenchymal stem cells transplantation on systemic lupus erythematosus].
abstract: OBJECTIVE
  To observe the efficacy of umbilical cord mesenchymal stem cells (UC-MSCs) transplantation for the patients with refractory systemic lupus erythematosus (SLE).
  
  
  METHODS
  Thirty seven patients with SLE were enrolled in this study, and divided into conventional treatment group (control group, n = 20) and UC-MSCS adjuvant treatment group (treatment group, n= 17). All the patients in both two groups were treated with glucocorticoids and cyclophosphamide (CTX). In the UC-MSCs group, each patient additionally received the transplantation of 3 x 10(7) UC-MSCs infusion intravenously. The clinical manifestations and laboratory parameters of each patient were observed before the treatments and 2 weeks, 1 month, 2 months, 3 months, months,9 months and 12 months after the treatments.
  
  
  RESULTS
  All the 37 patients were observed for 12 months. 24 h urinary protein excretion (U-Pro), anti nuclear antibody (ANA), erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), systemic lupus erythematosus disease activity index (SLEDAI) of these two groups decreased significantly (P < 0.05). serum albumin (ALB), C3, and C4 of two groups were higher after the treatments (P < 0.05). ALB and C3 in treatment group exceeded the control group (P < 0.05). The positive rates of Anti-dsDNA in control and treatment group were 40% and 10% respectively, while the recurrence rates were 50% and 20% respectively, these difference between the two groups were statistically significant (P < 0.05). There were no transplantation related complications observed.
  
  
  CONCLUSIONS
  UC-MSCs transplantation could be effective and safe for refractory SLE on basis of glucocorticoid and cyclophosphamide therapy.
authors.forename: Gui-Xian
authors.initials: GX
authors.lastname: Yang
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Pan
authors.forename: Qiao-Yan
authors.initials: QY
authors.lastname: Zhou
authors.forename: Wei
authors.initials: W
authors.lastname: Song
authors.forename: Zhi-Qin
authors.initials: ZQ
authors.lastname: Chen
authors.forename: Cheng-Xiao
authors.initials: CX
authors.lastname: Wang
authors.forename: Yan-Bo
authors.initials: YB
authors.lastname: Wu
authors.forename: Xi
authors.initials: X
authors.lastname: Wang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Chen
mesh_terms: D000974:Antibodies, Antinuclear / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells; D012008:Recurrence; D012709:Serum Albumin; D014470:Umbilical Cord / Q000166:cytology
chemical_list: D000974:Antibodies, Antinuclear; D005938:Glucocorticoids; D012709:Serum Albumin; D003520:Cyclophosphamide; D002097:C-Reactive Protein